Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model

Acta Oncologica

Volumn 44, Issue 3, 2005, Pages 293-298

  Vallbo, Christina ^a   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CD47 ANTIGEN; GELATINASE A; GELATINASE B; MESSENGER RNA; METALLOPROTEINASE; RECEPTOR; THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER GRADING; CANCER INHIBITION; CANCER MODEL; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD36; ANTIGENS, CD47; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM TRANSPLANTATION; PROSTATE; PROSTATIC NEOPLASMS; RATS; RNA, MESSENGER; SKIN NEOPLASMS; THROMBOSPONDIN 1; THROMBOSPONDINS;

EID: 21344438850     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410002806     Document Type: Conference Paper

References (31)

1. Rice A, Quinn CM. Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. J Clin Pathol 2002; 55(8):569-74.
2. Lawler J. The functions of thrombospondin-1 and -2. Curr Opin Cell Biol 2000;12(5):634-40.
3. Bertin N, Clezardin P, Kubiak R, Frappart L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 1997;57(3):396-9.
4. Yoshida Y, Oshika Y, Fukushima Y, Tokunaga T, Hatanaka H, Kijima H, et al. Expression of angiostatic factors in colorectal cancer. Int J Oncol 1999;15(6):1221-5.
5. Oshiba G, Kijima H, Himeno S, Kenmochi T, Kise Y, Tanaka H, et al. Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res 1999;19(5C):4375-8.
6. Tenan M, Fulci G, Albertoni M., Diserens AC, Hamou MF, El Atifi-Borel M, et al. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000;191(10):1789-98.
7. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002;89(3):303-9.
8. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49(4):293-305.
9. Vogel T, Guo NH, Krutzsch HC, Blake DA, Hartman J, Mendelovitz S, et al. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993;53(1):74-84.
10. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56(22):5279-84.
11. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.
12. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001;276(11):8403-8.
13. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000;275(41):32167-73.
14. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122(2):497-511.
15. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138(3):707-17.
16. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93(7):1159-70.
17. Massague J. Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem 1990; 265(35):21393-6.
18. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994;124(1-2):183-93.
19. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996;271(1):21-4.
20. Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates alpha v beta 3 function through integrin-associated protein. J Cell Biol 1996;135(2):533-44.
21. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9(3): 261-81.
22. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000;37(3):209-18.
23. Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS, et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000;7(12):1537-42.
24. Slater M, Barden JA, Murphy CR. Changes in growth factor expression in the ageing prostate may disrupt epithelial-stromal homeostasis. Histochem J 2000;32(6):357-64.
25. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15(3):246-58.
26. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998;152(2):591-6.
27. Vallbo C, Wang W, Damber JE. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int 2004;93(9):1339-43.
28. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30(4):419-24.
29. Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, et al. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 2001;7(1):81-8.
30. Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng AC, et al. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology 2002;59(1): 97-102.
31. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6(1):41-8.